FLT3 exon 14 ins: Gene Variant Detail - Cancer Knowledgebase (CKB)

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02756962	Phase II	Midostaurin Cytarabine	Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance	Active, not recruiting	USA	0
NCT05554393	Phase II	Cytarabine + Daunorubicin Cytarabine + Daunorubicin + Venetoclax Azacitidine + Venetoclax	Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)	Recruiting	USA \| CAN	1
NCT06366789	Phase I	ZE46-0134	Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia	Not yet recruiting	AUS	0
NCT04209725	Phase II	CPX-351 + Quizartinib	A Study of CPX-351 (Vyxeos) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia	Terminated	USA	0
NCT05766514	Phase II	Cladribine + Cytarabine + Decitabine Decitabine + Venetoclax Azacitidine + Venetoclax	Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction	Not yet recruiting	USA	0
NCT06313437	Phase I	Cytarabine + Daunorubicin + Midostaurin + Revumenib Cytarabine + Midostaurin + Revumenib	Revumenib in Combination With 7+3 + Midostaurin in AML	Recruiting	USA	0
NCT02668653	Phase III	Cytarabine + Daunorubicin + Idarubicin Cytarabine + Daunorubicin + Idarubicin + Quizartinib	Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)	Completed	USA \| ROU \| POL \| ITA \| ISR \| HUN \| HRV \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BGR \| BEL \| AUS \| ARG	10
NCT05756777	Phase I	Gilteritinib + Ivosidenib Enasidenib + Gilteritinib	A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)	Recruiting	USA	0
NCT06022003	Phase II	Azacitidine + Gilteritinib	Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects >=18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (OGILAR)	Recruiting	FRA	0
NCT04817241	Phase Ib/II	Cytarabine + Daunorubicin Decitabine and Cedazuridine + Venetoclax	Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients	Active, not recruiting	USA	0
NCT05010122	Phase Ib/II	Decitabine and Cedazuridine + Gilteritinib + Venetoclax	ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Recruiting	USA	0
NCT02927262	Phase III	Gilteritinib	A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission	Completed	USA \| SWE \| ROU \| POL \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA	5
NCT05183035	Phase III	Azacitidine + Cytarabine + Fludarabine + Gemtuzumab ozogamicin + Venetoclax Azacitidine + Cytarabine + Fludarabine + Gemtuzumab ozogamicin	Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)	Recruiting	USA \| SWE \| NZL \| NOR \| NLD \| ITA \| ISR \| FRA \| FIN \| ESP \| DNK \| CZE \| CHE \| CAN \| BEL \| AUT \| AUS	2
NCT05024552	Phase I	CPX-351 + Gilteritinib	Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML	Recruiting	USA	0
NCT04027309	Phase III	Midostaurin Gilteritinib	A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML)	Active, not recruiting	SWE \| NOR \| NLD \| LTU \| IRL \| FRA \| FIN \| ESP \| DEU \| CHE \| BEL \| AUT \| AUS	0
NCT03661307	Phase Ib/II	Decitabine + Quizartinib + Venetoclax	Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome	Recruiting	USA	0
NCT06578247	Phase III	Cytarabine + Idarubicin Cytarabine + Idarubicin + Quizartinib Cytarabine + Daunorubicin Cytarabine + Daunorubicin + Quizartinib	Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML (QuANTUM-WILD)	Recruiting	USA \| SWE \| ROU \| POL \| NOR \| ITA \| HUN \| HRV \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS	8
NCT02752035	Phase II	Gilteritinib Azacitidine + Gilteritinib Azacitidine	A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy	Completed	USA \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	3
NCT05330377	Phase I	Cladribine + Cytarabine + Filgrastim + Gilteritinib + Mitoxantrone	GM-CLAG in Relapsed/Refractory FLT3-mutated AML	Withdrawn	USA	0
NCT04336982	Phase Ib/II	Azacitidine + CC-90009 + Venetoclax CC-90009 + Gilteritinib	A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia	Terminated	USA \| GBR \| FRA \| CAN \| BEL	0
NCT06152809	Phase I	Aldesleukin + CIML-NK cells + Venetoclax	CIML NK Cells With Venetoclax for AML	Recruiting	USA	0
NCT05697510	Phase I	Siltuximab	Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM (SILTUXILAM)	Recruiting	FRA	0
NCT02543879	Phase I	FT-1101 Azacitidine + FT-1101	Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies	Completed	USA	0
NCT05599360	Phase II	CPX-351 + Gemtuzumab ozogamicin	Vyxeos for Induction of Low- or Intermediate-risk.	Active, not recruiting	ISR	0
NCT04493138	Phase Ib/II	Azacitidine + Quizartinib	Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations	Recruiting	USA	0
NCT03250338	Phase III	Cytarabine + Filgrastim + Fludarabine + Idarubicin + Mitoxantrone Crenolanib + Cytarabine + Filgrastim + Fludarabine + Idarubicin + Mitoxantrone	Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML	Unknown status	USA \| ITA \| FRA \| ESP \| DEU \| CAN	0
NCT03690115	Phase II	Ponatinib	Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients (PONALLO)	Completed	FRA	0
NCT04655391	Phase I	Glasdegib Glasdegib + Ivosidenib Bosutinib + Glasdegib Gilteritinib + Glasdegib Decitabine + Glasdegib + Venetoclax Enasidenib + Glasdegib	Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation	Withdrawn	USA	0
NCT03513484	Phase I	Azacitidine + Nintedanib	Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia	Active, not recruiting	USA	0
NCT03836209	Phase II	Cytarabine + Daunorubicin + Gilteritinib Cytarabine + Daunorubicin + Midostaurin Cytarabine Midostaurin	Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia	Active, not recruiting	USA	0
NCT06235801	Phase Ib/II	Gilteritinib + Momelotinib	A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia	Recruiting	USA	0
NCT03552029	Phase I	Milademetan + Quizartinib	Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)	Terminated	USA	0
NCT04669067	Phase Ib/II	KRT-232 + TL-895	TL-895 and KRT-232 Study in Acute Myeloid Leukemia	Active, not recruiting	USA \| ITA \| FRA \| ESP \| DEU \| AUT \| AUS	1
NCT03793478	Phase Ib/II	Etoposide Cytarabine + Fludarabine + Methotrexate + Prednisolone + Quizartinib Cytarabine + Daunorubicin + Fludarabine + Methotrexate + Prednisolone + Quizartinib Cytarabine + Daunorubicin + Fludarabine + Hydrocortisone + Methotrexate + Quizartinib Cytarabine + Fludarabine + Methotrexate + Prednisolone Quizartinib	Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood	Active, not recruiting	USA \| SWE \| NLD \| ITA \| ISR \| FRA \| ESP \| DNK \| CAN \| BEL	0
NCT04872478	Phase I	MRX-2843	Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults with Relapsed/Refractory AML, ALL, or MPAL	Recruiting	USA	0
NCT04168502	Phase III	Gemtuzumab ozogamicin	Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML	Recruiting	ITA	0
NCT02283177	Phase II	Crenolanib + Cytarabine + Daunorubicin	A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations	Completed	USA	0
NCT03735875	Phase Ib/II	Quizartinib + Venetoclax	Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia	Terminated	USA	0
NCT04385290	Phase Ib/II	Cytarabine + Daunorubicin + Gemtuzumab ozogamicin + Midostaurin Cytarabine + Daunorubicin + Gemtuzumab ozogamicin	Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) (MOSAIC)	Recruiting	DEU	0
NCT05546580	Phase I	Gilteritinib + ORY-1001	Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (FRIDA)	Recruiting	USA	0
NCT06504459	Phase II	Cladribine + Cytarabine + Venetoclax Azacitidine + Venetoclax	Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML	Recruiting	USA	0
NCT06782542	Phase II	Azacitidine + Olutasidenib + Venetoclax	Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy (OLUVENAZA)	Not yet recruiting	USA	0
NCT06222580	Phase I	Gilteritinib + Revumenib	SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation	Recruiting	USA	0
NCT04518345	Phase Ib/II	Dubermatinib Azacitidine + Dubermatinib	TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia	Completed	USA	0
NCT02270463	Phase Ib/II	Tagraxofusp-erzs	SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission	Terminated	USA	0
NCT01892371	Phase Ib/II	Azacitidine + Quizartinib Cytarabine + Quizartinib	Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Completed	USA	0
NCT03922100	Phase Ib/II	NMS-P088	Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML	Terminated	ITA \| FRA \| ESP	0
NCT03674411	Phase II	Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus	Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy	Active, not recruiting	USA	0
NCT06317649	Phase II	Azacitidine + Gilteritinib + Venetoclax Azacitidine + Venetoclax	Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)	Recruiting	USA	1
NCT02400255	Phase II	Crenolanib	Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients	Completed	USA	0
NCT03709758	Phase I	Cytarabine + Daunorubicin + Venetoclax	Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naive AML	Recruiting	USA	0
NCT05520567	Phase Ib/II	Azacitidine + Gilteritinib + Venetoclax	A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia	Recruiting	USA	0
NCT04107727	Phase II	Cytarabine Cytarabine + Idarubicin Cytarabine + Idarubicin + Quizartinib Quizartinib Cytarabine + Quizartinib	Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)	Unknown status	ESP	0
NCT05558124	Phase I	CPX-351 + Gemtuzumab ozogamicin	CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML	Recruiting	USA	0
NCT02039726	Phase III	Cytarabine + Fludarabine Cytarabine + Etoposide + Mitoxantrone Quizartinib Filgrastim + Idarubicin	(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive	Completed	USA \| POL \| NLD \| ITA \| HUN \| HRV \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BEL \| AUS	5
NCT05554406	Phase II	Cytarabine + Daunorubicin Azacitidine + Venetoclax CPX-351 Cytarabine + Daunorubicin + Venetoclax CPX-351 + Venetoclax	Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)	Recruiting	USA \| CAN	1
NCT04240002	Phase Ib/II	Cytarabine + Filgrastim + Fludarabine + Gilteritinib	A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)	Terminated	USA \| ITA \| GBR \| ESP \| DEU	0
NCT02997202	Phase III	Gilteritinib	A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)	Completed	USA \| POL \| NZL \| ITA \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BEL \| AUS	3
NCT05886049	Phase I	Cytarabine + Daunorubicin + Revumenib	Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene	Recruiting	USA	0
NCT04140487	Phase Ib/II	Azacitidine + Gilteritinib + Venetoclax	Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm	Recruiting	USA	0
NCT03365661	Phase II	Nogapendekin alfa inbakicept	QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML	Withdrawn	USA	0
NCT06366789	Phase I	ZE46-0134	Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia	Not yet recruiting	AUS	0

Gene	FLT3
Variant	exon 14 ins
Impact List	indel
Protein Effect	gain of function - predicted
Gene Variant Descriptions	FLT3 exon 14 ins refers to a series of internal tandem duplications (ITD) typically occurring in exon 14 and within the juxtamembrane domain of the Flt3 protein (PMID: 12970773). Exon 14 ins mutations often result in constitutive activation of Flt3 (PMID: 12970773) and therefore, is predicted to lead to a gain of Flt3 protein function.
Associated Drug Resistance
Category Variants Paths	FLT3 mutant FLT3 act mut FLT3 exon 14 ins FLT3 mutant FLT3 exon14 FLT3 exon 14 ins

We’re improving your experience!

FLT3 exon 14 ins - Gene Variant Detail

Contact

Filtering

Sorting

Filtering

Sorting